Clinical case use bevacizumab for patient with metastatic ovarian cancer
https://doi.org/10.17650/1994-4098-2014-0-2-68-72
Abstract
High incidence and mortality rate for ovarian cancer patients, short-term survival until relapse, repeated following surgeries and chemo- therapy, and also low survival rates make the problem of treatment of this pathology vital. Nowadays combination of platinum and paclitaxel (gemcitabine) in addition with targeted therapy (bevacizumab) is the most effective chemotherapy for first and second line of stages III and IV ovarians cancer. Considering high efficacy of these combinations aimed at the improving of the results of survival, further study of the use of bevacizumab in metastatic ovarian cancer therapy is necessary.
М.Р. Оганян, О.В. Давиденко
ГБУЗ «Клинический онкологический диспансер No 1» Минздрава Краснодарского края, Краснодар Контакты: Мариэтта Рафаэловна Оганян kapurol@mail.ru
About the Authors
M. R. Oganyan
Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar
Russian Federation
Russian Federation
O. V. Davidenko
Clinical Oncology Dispensary One, Ministry of Health of the Krasnodar Territory, Krasnodar
Russian Federation
Russian Federation
References
1. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71–96.
2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Ovarian Cancer 2013.
3. du Bois A., Quinn M., Thigpen T. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl 8:viii7–12.
4. Ozols R.F., Bundy B.N., Greer B.E. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194– 200.
5. du Bois A., Lück H.J., Meier W. et al. A randomized clinical trial of cisplatin/ paclitaxel versus carboplatin/paclitaxel as first- line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320–9.
6. Harries M., Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002;3(9):529–36.
7. Piccart M.J., Bertelsen K., James K. et al. Randomized intergroup trial of cisplatin- paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92(9):699–708.
8. Ledermann J.A., Raja F. Management strategies for partially platinum-sensitive ovarian cancer. Am J Cancer 2006;5:341–54.
9. Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 2003; 21(10 Suppl):149s–67s.
10. Sullivan D.С., Bicknell R. New molecular pathways in angiogenesis. Br J Cancer 2003;89(2):228–31.
11. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5(4):194–204.
12. Hartenbach E.M., Olson T.A., Goswitz J.J. et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121(2):169–75.
13. Burger R.A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121(1):230–8.
14. Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100(1):1–7.
15. Teoh D.G., Secord A.A. Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 2011;18(1):31–43.
16. Kabbinavar F.F., Wong J.T., Ayala R.E. et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res 1995;36:488.
17. Perren T., Swartz A.M,. Pfisterer J. et al. ICON7: A phase III randomised Gynaecologic Cancer Intergroup Trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010;21(Suppl 8): аbstr LBA4.
18. Burger R.A., Brady M.F., Bookman M.A. et al. Phase III trial of bevacizumab (BEV)
19. in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010;28(suppl):аbstr LBA1.
20. Burger R.A., Brady M.F., Rhee J. et al. Independent radiologic review of the Gynecologic Oncology Group study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Gynecol Oncol 2013;131(1): 21–6.
21. Penson R.T., Dizon D.S., Cannistra S.A. et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010;28:154–9.
22. Burger R.A., Sill M.W., Monk B.J. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: а Gynecologic Oncology Group study. J Clin Oncol 2007;25(33):5165–71.
23. Garcia A.A., Hirte H., Fleming G. et al. Phase II clinical trial of bevacizumab and low- dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret
24. Hospital рhase II сonsortia. J Clin Oncol 2008;26(1):76–82.
25. McGonigle K.F., Muntz H.G., Vuky J. et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum- resistant ovarian, primary peritoneal, or fallopian tube cancer (OV). J Clin Oncol 2008;26 (15 Suppl):abstr 5551.
26. Aghajanian C., Blank S.V., Goff B.A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039–45.
Review
For citations:
Oganyan M.R., Davidenko O.V. Clinical case use bevacizumab for patient with metastatic ovarian cancer. Tumors of female reproductive system. 2014;(2):68-72. (In Russ.) https://doi.org/10.17650/1994-4098-2014-0-2-68-72
Views:
865
Email this article 